Business Description
ASKA Pharmaceutical Holdings Co Ltd
ISIN : JP3119660003
Total Employee Number:
1,769Description
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.96 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 1.13 | |||||
Interest Coverage | 26.28 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.13 | |||||
Beneish M-Score | -2.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.4 | |||||
3-Year EBITDA Growth Rate | 5.7 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year FCF Growth Rate | 9.4 | |||||
3-Year Book Growth Rate | 8.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.25 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.6 | |||||
9-Day RSI | 39.16 | |||||
14-Day RSI | 38.18 | |||||
3-1 Month Momentum % | -20.06 | |||||
6-1 Month Momentum % | 8.11 | |||||
12-1 Month Momentum % | -4.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.76 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 276.09 | |||||
Days Sales Outstanding | 86.47 | |||||
Days Payable | 62.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.67 | |||||
Dividend Payout Ratio | 0.39 | |||||
3-Year Dividend Growth Rate | 55.4 | |||||
Forward Dividend Yield % | 2.94 | |||||
5-Year Yield-on-Cost % | 2.67 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -1.58 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48.01 | |||||
Operating Margin % | 8.2 | |||||
Net Margin % | 7.63 | |||||
EBITDA Margin % | 14.25 | |||||
FCF Margin % | 4.82 | |||||
OCF Margin % | 8.86 | |||||
ROE % | 8.05 | |||||
ROA % | 5.01 | |||||
ROIC % | 5.2 | |||||
3-Year ROIIC % | 2.39 | |||||
ROC (Joel Greenblatt) % | 14.35 | |||||
ROCE % | 8.48 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.74 | |||||
Forward PE Ratio | 13.65 | |||||
PE Ratio without NRI | 14.62 | |||||
Price-to-Owner-Earnings | 15.32 | |||||
PS Ratio | 0.9 | |||||
PB Ratio | 0.91 | |||||
Price-to-Tangible-Book | 1.04 | |||||
Price-to-Free-Cash-Flow | 18.57 | |||||
Price-to-Operating-Cash-Flow | 10.1 | |||||
EV-to-EBIT | 9.79 | |||||
EV-to-EBITDA | 6.97 | |||||
EV-to-Revenue | 0.99 | |||||
EV-to-FCF | 20.59 | |||||
Price-to-GF-Value | 0.93 | |||||
Price-to-Graham-Number | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
Earnings Yield (Greenblatt) % | 10.21 | |||||
FCF Yield % | 5.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ASKA Pharmaceutical Holdings Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 71,127 | ||
| EPS (TTM) (円) | 191.12 | ||
| Beta | 0.261 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.12 | ||
| Volatility % | 42.4 | ||
| 14-Day RSI | 38.18 | ||
| 14-Day ATR (円) | 69.281222 | ||
| 20-Day SMA (円) | 2283.9 | ||
| 12-1 Month Momentum % | -4.67 | ||
| 52-Week Range (円) | 1920 - 3045 | ||
| Shares Outstanding (Mil) | 28.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ASKA Pharmaceutical Holdings Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ASKA Pharmaceutical Holdings Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 32.000000 Cash Dividend | 2026-09-29 | In 71 days | ||
| JPY 33.000000 Cash Dividend | 2026-03-30 | 2,369.00 (+2.69%) | ||
| JPY 27.000000 Cash Dividend | 2025-09-29 | 2,369.00 (+0.00%) | ||
| JPY 30.000000 Cash Dividend | 2025-03-28 | 2,342.00 (+0.77%) | ||
| JPY 25.000000 Cash Dividend | 2024-09-27 | 2,232.00 (-0.40%) |
Show
Entries
ASKA Pharmaceutical Holdings Co Ltd Frequently Asked Questions
What is ASKA Pharmaceutical Holdings Co Ltd(TSE:4886)'s stock price today?
The current price of TSE:4886 is 円2244.00. The 52 week high of TSE:4886 is 円3045.00 and 52 week low is 円1920.00.
When is next earnings date of ASKA Pharmaceutical Holdings Co Ltd(TSE:4886)?
The next earnings date of ASKA Pharmaceutical Holdings Co Ltd(TSE:4886) is .
Does ASKA Pharmaceutical Holdings Co Ltd(TSE:4886) pay dividends? If so, how much?
The Dividend Yield %  of ASKA Pharmaceutical Holdings Co Ltd(TSE:4886) is 2.67% (As of Today), Highest Dividend Payout Ratio of ASKA Pharmaceutical Holdings Co Ltd(TSE:4886) was 0.39. The lowest was 0.11. And the median was 0.23. The  Forward Dividend Yield % of ASKA Pharmaceutical Holdings Co Ltd(TSE:4886) is 2.94%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ASKA Pharmaceutical Holdings Co Ltd
No articles.